Načítá se...
Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history
Asthma is a heterogeneous syndrome with numerous underlining molecular and inflammatory mechanisms contributing to the wide spectrum of clinical phenotypes. Multiple therapies targeting severe asthma with type 2 (T2) high inflammation are or soon will be available. T2 high inflammation is defined as...
Uloženo v:
| Vydáno v: | J Asthma Allergy |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5892947/ https://ncbi.nlm.nih.gov/pubmed/29662320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JAA.S107982 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|